Nkarta opened lower at $1.43, compared with its previous close of $1.48. In the last trading session, the stock traded between $1.26 and $1.43. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Nkarta is now worth
$ 6.89
Resulting in a loss of
$ 93.11 (93.11%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.22 (-14.53%)
Day High
$1.43
Day Low
$1.26
Day Open
$1.43
Prev Close
$1.48
Volume
9,16,305
1W Return
-26.67%
1M Return
-41.57%
3M Return
-45.43%
6M Return
-60.22%
1Y Return
-37.06%
Fundamentals
Market Cap ($ Mn)
91
PE Ratio
-
PB Ratio
0.80
PEG Ratio
-
ROE
-29.00%
ROCE
-27.76%
EPS (TTM)
$-0.47
Investment Returns
1 Week
-26.67%
1 Month
-41.57%
3 Months
-45.43%
6 Months
-60.22%
9 Months
-36.75%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
11Nov
Nkarta reports zero CRS or ICANS across 40 patients in Ntrust trial
Zero cases of CRS, ICANS, or GvHD reported across 40 patients. 86% of systemic sclerosis patients achieved rCRISS-25 response. Median disease duration was 4.7 years in heavily pretreated cohort. Grade 3+ adverse events primarily attributed to lymphodepletion.
Yesterday
9Nov
Needham reiterates Buy rating on Nkarta, maintains $11 price target
Needham analyst Gil Blum reiterated a Buy rating on Nkarta. The price target was maintained at $11 per share. No changes were made to the existing valuation estimates.
3 days ago
11Aug
Nkarta Q2 EPS of $(0.54) misses $(0.38) analyst estimate
Nkarta's Q2 2026 results show a net loss of $40.4 million and EPS of $(0.54), missing analyst estimates of $(0.38). The loss widened significantly compared to the prior year due to increased operating expenses, particularly in G&A. The company maintains $243.2 million in cash to support its clinical trials into 2029.
3mo ago
26Jun
Nkarta to present CAR-NK therapy updates at virtual conference
Nkarta, Inc. is set to present its CAR-NK cell therapy progress at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. President Nadir Mahmood will lead the discussion, which will be webcast live and archived for 90 days.
